## **Frans Rutten**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11188992/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cost-Effectiveness and Dynamic Efficiency: Does the Solution Lie Within?. Value in Health, 2017, 20, 240-243.	0.3	13
2	Impact of Communityâ€based Health Insurance on Access and Financial Protection: Evidence from Three Randomized Control Trials in Rural India. Health Economics (United Kingdom), 2016, 25, 675-687.	1.7	28
3	Economic consequences of ill-health for households in northern rural India. BMC Health Services Research, 2015, 15, 179.	2.2	30
4	Differences in Overweight and Obesity among Children from Migrant and Native Origin: The Role of Physical Activity, Dietary Intake, and Sleep Duration. PLoS ONE, 2015, 10, e0123672.	2.5	26
5	What Do International Pharmacoeconomic Guidelines Say about Economic Data Transferability?. Value in Health, 2010, 13, 1028-1037.	0.3	77
6	Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report. Value in Health, 2009, 12, 409-418.	0.3	395
7	The Impact of Healthcare Reform in The Netherlands. Pharmacoeconomics, 2004, 22, 65-71.	3.3	2
8	The Incorporation of Potential Confounding Variables in Markov Models. Pharmacoeconomics, 2003, 21, 941-950.	3.3	6
9	Combining a Budgetary-Impact Analysis and a Cost-Effectiveness Analysis Using Decision-Analytic Modelling Techniques. Pharmacoeconomics, 2002, 20, 855-867.	3.3	25
10	Handbook of Health Economics. Journal of Health Economics, 2001, 20, 855-879.	2.7	6
11	Current Trends in the Use of Pharmacoeconomics and Outcomes Research in Europe. Value in Health, 1999, 2, 323-332.	0.3	63
12	Assessment of biotechnology drugs: what are the issues?. Health Policy, 1999, 47, 255-274.	3.0	17
13	The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy, 1997, 40, 199-215.	3.0	105
14	Economic evaluation and health care decision-making. Health Policy, 1996, 36, 215-229.	3.0	25
15	Intergration of economic appraisal and health care policy in a health insurance system; The Dutch case. Social Science and Medicine, 1994, 38, 1609-1614.	3.8	10
16	Economic Evaluation of Pharmaceuticals. Pharmacoeconomics, 1993, 4, 173-186.	3.3	58
17	No cure, no pay: an acceptable way of financing fertility treatments?. Health Policy, 1989, 13, 239-249.	3.0	11